Leukemia Clinical Trials & Research

Eytan Stein at a computer with nurse practitioner Bernadette Cuello
Program for Drug Development in Leukemia
The Program for Drug Development in Leukemia offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials.
Learn more

Over the past several years, there has been an explosion in our understanding of the pathogenesis of both acute and chronic leukemia, the number of novel agents with unique mechanisms of action, and other new strategies, including immunologic approaches. Researchers at Memorial Sloan Kettering continue to pursue these and other treatment approaches in our clinical trials. 

Relying in part on the information that is emerging about the genetic basis of leukemia, investigators are pursuing approaches that can kill tumor cells directly, inhibit the body’s production of substances that promote their growth, or enhance the immune response against leukemic cells. 

Here you can find a continually updated listing of Memorial Sloan Kettering’s current clinical trials for adults with leukemia. Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

For clinical trials for children with leukemia, please visit Pediatric Clinical Trials.

You can also visit our Blood & Marrow Stem Cell Transplantation Clinical Trials.

and/or
Reset
19 Clinical Trials found
A Phase 1 Study of 19-28z/IL-18 CAR T Cell Therapy in People With Acute Lymphoblastic Leukemia
Researchers are assessing a CAR T cell therapy to treat acute lymphoblastic leukemia (ALL) that keeps growing even with treatment. With CAR T cell therapy, some of your own T cells (a type of white blood cell) are removed. They are genetically modified (changed) in a lab to recognize your own cancer cells. The altered T cells, called CAR T cells, are then returned to your body to find and kill cancer cells. This treatment is a form of immunotherapy.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of TRX103 in People With Blood Cancers Receiving a Donated Stem Cell Transplant
Graft-versus-host disease (GVHD) is a serious condition that can happen after a stem cell transplant from a donor. The donated cells see the healthy tissues in the recipient's body as foreign and attack them. TRX103 is a new drug designed to reduce the risk of GVHD.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of Ziftomenib Plus Chemotherapy in Children and Young Adults With Acute Leukemia
Researchers are doing this study to find the best dose of ziftomenib to give with standard chemotherapy in children and young adults with acute leukemia. The people in this study have acute leukemia that keeps growing or came back after treatment. In addition, their cancers have a mutation (change) in the KMT2A, NUP98, or NPM1 genes.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study Assessing Total Therapy for Infants with Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) in infants (babies under 1 year of age) can be challenging to treat. Researchers in this study are assessing the addition of 2 new drugs to standard chemotherapy for ALL in infants.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Platform Study to Evaluate the Safety and Efficacy of Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
To learn more about the purpose of this study and to find out who can join, please click here for Substudy 01A or here for Substudy 01C to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Revumenib in People With Acute Leukemia
Researchers want to see how well revumenib works against acute leukemia. The people in this study have acute leukemia that keeps growing after treatment. They also have a mutation (change) in the HOX gene, which is related to new or immature leukemia cells.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Revumenib With Chemotherapy for Children with Recurrent or Persistent Infant Leukemia
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
New York City
A Phase 3 Study Assessing Dasatinib or Imatinib and Chemotherapy With and Without Blinatumomab for Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
New York City
A Phase 3 Study of Inotuzumab Ozogamicin and Standard Chemotherapy for Newly Diagnosed High-Risk B-Cell Acute Lymphocytic Leukemia, Mixed Acute Leukemia, and Disseminated B-LLy
The overall goal of this study is to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves treatment effectiveness in young patients with high-risk B cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin contains an antibody (inotuzumab) linked to a type of chemotherapy (calicheamicin). Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them.
New York City
A Phase I Study of UCART22 CAR T-Cell Therapy in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
New York City